FIRST DRAFT PROGRAM

TIME ON ADVANCES IN HAEMATOLOGICAL DISORDERS : THE “TARGET” THERAPY

January 30- 1 February 2014, PALERMO
Under the auspices of SIE

Scientific Coordinators: F. Pane and A. Maggio
Scientific Committee: Brugiatelli M., F. Di Raimondo F., Fabbiano F., Musso M., Scimè R., Siragusa S.

Aula Magna “Maurizio Vignola”
P.O. “V. Cervello” – Palermo

January 30

14:00 Greetings from health authority
14:15 Introduction to the meeting, F. Pane and A. Maggio

Hereditary disorders

Chairperson S. Acuto and S. Siragusa

14:30 Target treatment in thalassemia: which perspectives? Stamatoyannopoulos G
15:00 The target therapy of hemophilia B with IV administered AAV factor IX vectors, Nathwani A

Malignancies disorders

Chairperson: F. Pane

15:30 Emerging targets for hematological malignancies, Cilloni D
16:00 : Break

Acute Leukemia
Chairpersons F. Fabbiano and F Lo Coco

16:30 Acute myeloid leukemia biology: recurrent mutations, and analysis of PU.1 target genes, Takahashi S

17:00 MoAbs in Acute Leukemia. Pane F

17:30 Retinoic acid and arsenic trioxide for acute promyelocytic leukemia, Lo Coco F

18:00 The promise of T cell engineering to treat leukemia and other cancers, Sadelain M

Chairpersons Cilloni D and Santoro A

18:30 Poster and oral session on Acute Leukemia: 6 oral presentations and 15 posters will be selected by the scientific committee

20:00 Conclusions: F Pane

January 31

Myeloproliferative disorders

Chairpersons F Di Raimondo and M Musso

9:00 Genetic complexity of myeloproliferative neoplasms, Rumi E

9:30 The role of JAK inhibitors in myeloproliferative neoplasms, Guglielmelli P

10:00 Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy, Finazzi G

10:30 A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia, Andersen C

11:00 Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia Saglio G

11:30 Break
Chairpersons Rumi E and Andersen C

12:00 Poster and oral session on Myeloproliferative disorders: 6 oral presentations and 15 posters will be selected by the scientific committee

13:30 Lunch

Chairperson G Stamatoyannopoulos

14:30 Cao and Galanello lecture. This lecture will be assigned by the scientific committee among haematologist researchers who developed significant progress on “target” treatment in hematology during 2013

*Lymphoproliferative disorders*

Chairpersons PL Zinzani and K Patti

15:30 Genetic aberrations of signaling pathways in lymphomagenesis: revelations from next generation sequencing studies, Rossi D

16:00 Overview of alemtuzumab therapy for the treatment of T-cell lymphomas. Zinzani PL.

16:30 Break

Chairpersons M Brugiatelli and D Rossi

17:00 Poster and oral session on Lymphoproliferative disorders: 6 oral presentations and 15 posters will be selected by the scientific committee

18:30 Conclusions: A Maggio

20:30 Gala Dinner

February 1

*Myelodisplasia*

Chairpersons R Scimè R and M Cazzola

9:30 MDS today: which news and future perspectives? Cazzola M
10:00 Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidine. Fenaux P

10:30 Pathophysiological and clinical aspects of iron chelation therapy in MDS. Angelucci E

11:00 Poster and oral session on Myelodisplasia: 6 oral session and 15 posters will be selected by the scientific committee

12:30 Conclusions F Pane and A Maggio

Time on advances in hematological disorders has the ambition to address, every year, attention on new highlights in this field, including oncological and non-oncological diseases. To obtain this aim a selected number of international “opinion leaders” will talk about specific “items” and these will be discussed through a brainstorming session with all participants.

This year the main topics of this meeting will be the “target” therapy.

 Actually, the hard progress, during these last years, determined by the use of “drug” working on specific gene or on pathway as antigens, tyrosine-kinase or other molecules with main effect on cell-cycle, is changing our treatment approach. Moreover, this strategy is gradually improving prognosis of different hereditary and acquired haematological diseases.

It seems yesterday, when YW Kan from Howard Hughes Medical Institute Laboratory in San Francisco, published, on March 1992 JAMA issue, the development of DNA analysis for human diseases applied to Sickle-Cell-Anemia and Thalassemia. During that time, researchers were aware that one gene means one disease. Therefore, correction of single gene mutation could cure the single disease. However, time showed as this issue was more complicated in comparison with it was previously thought. The detection of different mutations for the single disease, the involvement of several factors interacting with expression, the influence of other genes, enzyme or protein, involved on the cell-cycle, suggested as it was necessary to find different approaches for the “target” therapy. Thanks to this new strategy, today we may state that the use of tyrosine-kinase-inhibitors is opening the way for the definitive cure from myeloid chronic leukaemia.

This meeting has the ambition to put together an international panel of researchers with high expertise on “target” therapy on genetic and acquired haematological diseases.

Moreover, this meeting will host the Cao and Galanello lecture. This lecture, in memory of Prof. Antonio Cao and Prof. Renzo Galanello, pioneer researchers in thalassemia field, will be assigned by the scientific committee to a scientist who, during the last year, performed the most striking progress on target “treatment”.

We hope that you will enjoy meeting and that this event could be useful for stimulating new ideas about possible research on this field.